Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;32(3):351-359.
doi: 10.1016/j.annonc.2020.12.008. Epub 2021 Jan 29.

A prospective study of type 2 diabetes, metformin use, and risk of breast cancer

Y-M M Park  1 , D B Bookwalter  2 , K M O'Brien  3 , C L Jackson  4 , C R Weinberg  5 , D P Sandler  6
Affiliations

A prospective study of type 2 diabetes, metformin use, and risk of breast cancer

Y-M M Park et al. Ann Oncol. 2021 Mar.

Abstract

Background: Type 2 diabetes (T2D) has been associated with increased breast cancer risk, but commonly prescribed antidiabetic medications such as metformin may reduce risk. Few studies have investigated T2D and medications together in relation to breast cancer.

Patients and methods: Data came from 44 541 Sister Study participants aged 35 to 74 years at enrollment (2003-2009) who satisfied eligibility criteria, followed through 15 September 2017. Information on time-varying, self-reported, physician-diagnosed, prevalent and incident T2D, use of antidiabetic medications, and covariates was obtained from baseline and follow-up questionnaires. Incident breast cancers were confirmed with medical records. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated.

Results: During follow-up (median, 8.6 years), 2678 breast cancers were diagnosed at least 1 year after enrollment. There were 3227 women (7.2%) with prevalent and 2389 (5.3%) with incident T2D, among whom 61% (n = 3386) were ever treated with metformin. There was no overall association between T2D and breast cancer risk (HR 0.99; 95% CI, 0.87-1.13). However, T2D was associated with increased risk of triple-negative breast cancer (HR 1.40; 95% CI, 0.90-2.16). Compared with not having T2D, T2D with metformin use was not associated with overall breast cancer risk (HR 0.98; 95% CI, 0.83-1.15), but it was associated with decreased risk of estrogen receptor (ER)-positive breast cancer (HR 0.86; 95% CI 0.70-1.05) and increased risk of ER-negative (HR 1.25; 95% CI, 0.84-1.88) and triple-negative breast cancer (HR 1.74; 95% CI, 1.06-2.83). The inverse association with ER-positive cancer was stronger for longer duration (≥10 year) metformin use (HR 0.62; 95% CI, 0.38-1.01; P for trend = 0.09). Results were supported by sensitivity analyses.

Conclusion: Our findings suggest that associations between T2D and breast cancer may differ by hormone receptor status and that associations between T2D and ER-positive breast cancer may be reduced by long-term metformin use.

Keywords: antidiabetic medication; breast cancer; estrogen receptor; metformin; triple-negative; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have declared no conflicts of interest.

Comment in

References

    1. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856–862. - PubMed
    1. Boyle P, Boniol M, Koechlin A et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 2012; 107: 1608–1617. - PMC - PubMed
    1. Wolf I, Sadetzki S, Catane R et al. Diabetes mellitus and breast cancer. The Lancet Oncology 2005; 6: 103–111. - PubMed
    1. Bailey CJ. Metformin: historical overview. Diabetologia 2017; 60: 1566–1576. - PubMed
    1. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol 2009; 27: 3271–3273. - PubMed

Publication types